MedTrace Logo

Immunomonitoring of Mold Invasive Infections

NCT06285188 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-11-20

No results posted yet for this study

Summary

Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.

Conditions

  • Invasive Fungal Disease
  • Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Fanny LANTERNIER, MD, PhD · APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-28
Primary Completion
2027-04-30
Completion
2027-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06285188 on ClinicalTrials.gov